Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models | Science Translational Medicine
Antagonizing the VIP-VIPR pathway results in phenotypically and functionally superior CAR T cells that boost endogenous immunity.
